1. Home
  2. ASMB vs KPTI Comparison

ASMB vs KPTI Comparison

Compare ASMB & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

N/A

Current Price

$22.95

Market Cap

512.1M

Sector

Health Care

ML Signal

N/A

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

N/A

Current Price

$0.88

Market Cap

36.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASMB
KPTI
Founded
2005
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
512.1M
36.7M
IPO Year
2010
2013

Fundamental Metrics

Financial Performance
Metric
ASMB
KPTI
Price
$22.95
$0.88
Analyst Decision
Strong Buy
Buy
Analyst Count
5
5
Target Price
★ $52.00
$7.25
AVG Volume (30 Days)
292.3K
★ 1.2M
Earning Date
11-09-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 91.78
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $146,067,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$27.98
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 0.57
52 Week Low
$21.80
$1.20
52 Week High
$39.71
$10.99

Technical Indicators

Market Signals
Indicator
ASMB
KPTI
Relative Strength Index (RSI) 27.24 23.57
Support Level $21.80 N/A
Resistance Level $30.36 $2.16
Average True Range (ATR) 1.22 0.16
MACD -0.41 0.04
Stochastic Oscillator 1.75 0.00

Price Performance

Historical Comparison
ASMB
KPTI

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

Share on Social Networks: